Compare AMPX & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPX | KLRA |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2022 | 2026 |
| Metric | AMPX | KLRA |
|---|---|---|
| Price | $10.34 | $17.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $20.17 | N/A |
| AVG Volume (30 Days) | ★ 5.8M | 525.5K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,011,000.00 | N/A |
| Revenue This Year | $76.15 | N/A |
| Revenue Next Year | $59.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 202.11 | N/A |
| 52 Week Low | $6.66 | $16.39 |
| 52 Week High | $24.23 | $23.82 |
| Indicator | AMPX | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 40.25 |
| Support Level | $9.30 | $16.39 |
| Resistance Level | $13.00 | $19.13 |
| Average True Range (ATR) | 0.75 | 1.00 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 12.50 | 9.83 |
Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. Its silicon anodes are a direct drop-in replacement of the graphite anode in traditional lithium-ion batteries, and its manufacturing processes leverage the manufacturing processes for conventional lithium-ion batteries and the related supply chain.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.